PDCD1 and hepatocellular carcinoma: Immunotherapy, especially the targeting of the immune checkpoint blockade (ICB) against programmed cell death protein 1 (PD-1) or its ligand (PD-L1), has risen as a significant advancement in the treatment of HCC [3, 4].